{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:37:03Z","timestamp":1774305423037,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Inner Mongolia Autonomous Region science and technology plan project","award":["2019GG047"],"award-info":[{"award-number":["2019GG047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Genotype status of glioma have important significance to clinical treatment and prognosis. At present, there are few studies on the prediction of multiple genotype status in glioma by method of multi-sequence radiomics. The purpose of the study is to compare the performance of clinical features (age, sex, WHO grade, MRI morphological features etc.), radiomics features from multi MR sequence (T2WI, T1WI, DWI, ADC, CE-MRI (contrast enhancement)), and a combined multiple features model in predicting biomarker status (IDH, MGMT, TERT, 1p\/19q of glioma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective analysis, 81 glioma patients confirmed by histology were enrolled in this study. Five MRI sequences were used for radiomic feature extraction. Finally, 107 features were extracted from each sequence on Pyradiomics software, separately. These included 18 first-order metrics, such as the mean, standard deviation, skewness, and kurtosis etc., 14 shape features and second-order metrics including 24 grey level run length matrix (GLCM), 16 grey level run length matrix (GLRLM), 16 grey level size zone matrix (GLSZM), 5 neighboring gray tone difference matrix (NGTDM), and 14 grey level dependence matrix (GLDM). Then, Univariate analysis and LASSO (Least absolute shrinkage and selection operator regression model were used to data dimension reduction, feature selection, and radiomics signature building. Significant features (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 by multivariate logistic regression were retained to establish clinical model, T1WI model, T2WI model, T1\u2009+\u2009C (T1WI contrast enhancement model, DWI model and ADC model, multi sequence model. Clinical features were combined with multi sequence model to establish a combined model. The predictive performance was validated by receiver operating characteristic curve (ROC analysis and decision curve analysis (DCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The combined model showed the better performance in some groups of genotype status among some models (IDH AUC\u2009=\u20090.93, MGMT AUC\u2009=\u20090.88, TERT AUC\u2009=\u20090.76). Multi sequence model performed better than single sequence model in IDH, MGMT, TERT. There was no significant difference among the models in predicting 1p\/19q status. Decision curve analysis showed combined model has higher clinical benefit than multi sequence model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Multi sequence model is an effective method to identify the genotype status of cerebral glioma. Combined with clinical models can better distinguish genotype status of glioma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Points<\/jats:title><jats:p><jats:list list-type=\"bullet\"><jats:list-item><jats:p>The combined model showed the higher performance compare with other models in predicting genotype status of IDH, MGMT, TERT.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Multi sequence model showed a better predictive model than that of a single sequence model.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Compared with other models, the combined model and multi sequence model show no advantage in prediction of 1p\/19q status.<\/jats:p><\/jats:list-item><\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1186\/s12880-022-00865-8","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T09:04:53Z","timestamp":1659690293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status"],"prefix":"10.1186","volume":"22","author":[{"given":"Jinlong","family":"He","sequence":"first","affiliation":[]},{"given":"Jialiang","family":"Ren","sequence":"additional","affiliation":[]},{"given":"Guangming","family":"Niu","sequence":"additional","affiliation":[]},{"given":"Aishi","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Shenghui","family":"Xie","sequence":"additional","affiliation":[]},{"given":"Xueying","family":"Ma","sequence":"additional","affiliation":[]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[]},{"given":"Jianlin","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"Suppl 4","key":"865_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/neuonc\/nou223","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro Oncol. 2014;16(Suppl 4):41\u201363.","journal-title":"Neuro Oncol."},{"issue":"1","key":"865_CR2","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41598-018-25169-2","volume":"8","author":"AA Pandith","year":"2018","unstructured":"Pandith AA, Qasim I, Zahoor W, et al. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Sci Rep. 2018;8(1):6704.","journal-title":"Sci Rep"},{"issue":"2","key":"865_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00330-018-5575-z","volume":"29","author":"J We","year":"2019","unstructured":"We J, Yang G, Hao X, et al. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Eur Radiol. 2019;29(2):877\u201388.","journal-title":"Eur Radiol"},{"issue":"11","key":"865_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/neuonc\/nox054","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19(11):1460\u20138.","journal-title":"Neuro Oncol"},{"issue":"11","key":"865_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580\u20139.","journal-title":"Br J Cancer"},{"issue":"8","key":"865_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"3","key":"865_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"865_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.3390\/ijms22052492","volume":"22","author":"IMA Al-Obaide","year":"2021","unstructured":"Al-Obaide IMA, Arutla V, et al. Genomic space of MGMT in human glioma revisited: novel motifs, regulatory RNAs, NRF1, 2, and CTCF involvement in gene expression. Int J Mol Sci. 2021;22(5):2492.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"865_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ Bent","year":"2013","unstructured":"Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013;31(3):344\u201350.","journal-title":"J Clin Oncol"},{"issue":"26","key":"865_CR10","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RGW, Dape KDA, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481\u201398.","journal-title":"N Engl J Med."},{"key":"865_CR11","doi-asserted-by":"publisher","first-page":"616740","DOI":"10.3389\/fonc.2021.616740","volume":"11","author":"Z Fan","year":"2021","unstructured":"Fan Z, Sun Z, Fang S, et al. Preoperative radiomics analysis of 1p\/19q status in WHO grade II gliomas. Front Oncol. 2021;11:616740.","journal-title":"Front Oncol"},{"issue":"1","key":"865_CR12","first-page":"vdaa025","volume":"2","author":"B Patel","year":"2020","unstructured":"Patel B, Taiwo R, Kim AH, et al. TERT, a promoter of CNS malignancies. Neurooncol Adv. 2020;2(1):vdaa025.","journal-title":"Neurooncol Adv."},{"issue":"15","key":"865_CR13","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15):6021\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"865_CR14","doi-asserted-by":"publisher","first-page":"10617","DOI":"10.18632\/oncotarget.3329","volume":"6","author":"B Heidenreich","year":"2015","unstructured":"Heidenreich B, Rachakonda PS, Hosen I, et al. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget. 2015;6(12):10617\u201333.","journal-title":"Oncotarget"},{"issue":"21","key":"865_CR15","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Can Res. 2017;77(21):e104\u20137.","journal-title":"Can Res"},{"issue":"1","key":"865_CR16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shriknage and selectino via the lasso. J R Stat Soc Ser B. 1996;58(1):267\u201388.","journal-title":"J R Stat Soc Ser B"},{"issue":"1","key":"865_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15446\/rce.v43n1.80000","volume":"43","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, He J, Chalise P. Nested and repeated cross validation for classification model with highdimensional data. Rev Colomb Estad. 2020;43(1):103\u201325.","journal-title":"Rev Colomb Estad"},{"issue":"3","key":"865_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL, et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"key":"865_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-41021-00205-z","author":"J Yan","year":"2021","unstructured":"Yan J, Zhang B, Zhang S, et al. Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. NPJ Precis Oncol. 2021. https:\/\/doi.org\/10.1038\/s41698-41021-00205-z.","journal-title":"NPJ Precis Oncol."},{"issue":"2","key":"865_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11060-019-03096-0","volume":"142","author":"H Zhou","year":"2019","unstructured":"Zhou H, Chang K, Bai HX, et al. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p\/19q status in diffuse lowand high-grade gliomas. J Neurooncol. 2019;142(2):299\u2013307.","journal-title":"J Neurooncol"},{"issue":"1","key":"865_CR21","first-page":"vdab051","volume":"3","author":"S Kihira","year":"2021","unstructured":"Kihira S, Tsankova NM, Bauer A, et al. Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion. Neurooncol Adv. 2021;3(1):vdab051.","journal-title":"Neurooncol Adv."},{"issue":"1","key":"865_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.18632\/oncotarget.13329","volume":"8","author":"LE Huang","year":"2017","unstructured":"Huang LE, Cohen AL, Colman H, et al. IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget. 2017;8(1):191\u2013202.","journal-title":"Oncotarget"},{"issue":"17","key":"865_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","volume":"75","author":"C Houillier","year":"2010","unstructured":"Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560\u20136.","journal-title":"Neurology"},{"issue":"1","key":"865_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/neuonc\/nos261","volume":"15","author":"S Li","year":"2013","unstructured":"Li S, Chou AP, Chen W, et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013;15(1):57\u201368.","journal-title":"Neuro Oncol"},{"issue":"18","key":"865_CR25","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1158\/1078-0432.CCR-13-0017","volume":"19","author":"C Hartmann","year":"2013","unstructured":"Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146\u201357.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"865_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"6","key":"865_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00401-013-1163-0","volume":"126","author":"N Nonoguchi","year":"2013","unstructured":"Nonoguchi N, Ohta T, Oh J-E, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013;126(6):931\u20137.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"865_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0090-3019(03)00167-8","volume":"60","author":"HH Engelhard","year":"2003","unstructured":"Engelhard HH, Ana Stelea AM. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol. 2003;60(5):443\u201356.","journal-title":"Surg Neurol"},{"key":"865_CR29","doi-asserted-by":"publisher","first-page":"11022","DOI":"10.1038\/s41598-020-68102-2","volume":"10","author":"J Yao","year":"2020","unstructured":"Yao J, Hagiwara A, Raymond C, et al. Human IDH mutant 1p\/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Sci Rep. 2020;10:11022.","journal-title":"Sci Rep."},{"issue":"4","key":"865_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/diagnostics10040247","volume":"10","author":"P Feraco","year":"2020","unstructured":"Feraco P, Bacci A, Ferrazza P, et al. Magnetic resonance imaging derived biomarkers of IDH mutation status and overall survival in grade III astrocytomas. Diagnostics. 2020;10(4):247.","journal-title":"Diagnostics"},{"key":"865_CR31","doi-asserted-by":"publisher","first-page":"640738","DOI":"10.3389\/fonc.2021.640738","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Peng H, Wang Y-L, et al. Predictive role of the apparent diffusion coefficient and MRI morphologic features on IDH status in patients with diffuse glioma: a retrospective cross-sectional study. Front Oncol. 2021;11:640738.","journal-title":"Front Oncol"},{"issue":"9","key":"865_CR32","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/1078-0432.CCR-06-2184","volume":"13","author":"M Eoli","year":"2007","unstructured":"Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and\/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007;13(9):2606\u201313.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"865_CR33","first-page":"1439","volume":"39","author":"CH Suh","year":"2018","unstructured":"Suh CH, Kim HS, Jung SC, et al. Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2018;39(8):1439\u201345.","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00865-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:24:43Z","timestamp":1727727883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00865-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki. We confirm that all methods were carried out in accordance with relevant guidelines and regulations. The Ethics Committee of the Affiliated Hospital of Inner Mongolia Medical University approved this retrospective single institution study and waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"One of the authors of this manuscript (JiaLiang Ren) is an employee GE Healthcare. The remaining authors declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}